Bard Discontinues Tegress Incontinence Product Due To Postmarket Expense
This article was originally published in The Gray Sheet
Executive Summary
Bard will halt sales of its urinary incontinence bulking agent Tegress while continuing to offer its Contigen collagen-based device, citing excessive costs associated with Tegress' postmarket requirements
You may also be interested in...
Mayo Clinic Looks At The Heart In Five Dimensions
Mayo Clinic researchers are aiming to conduct large-scale clinical trials in 2008 of a five-dimensional imaging tool for treatment of atrial fibrillation
Mayo Clinic Looks At The Heart In Five Dimensions
Mayo Clinic researchers are aiming to conduct large-scale clinical trials in 2008 of a five-dimensional imaging tool for treatment of atrial fibrillation
Bard Pushes Back Expected Launch Date For AF Ablation Catheter
Stringent FDA clinical trial requirements have caused C.R. Bard to push back the U.S. launch timeline for its RF mesh ablation catheter for atrial fibrillation to late 2008 or 2009. The company had hoped to release the product almost one year sooner